Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate EC-18 for Oral Mucositis in Patients With Concomitant Chemoirradiation for Cancers of the Mouth, Oropharynx, Hypopharynx and Nasopharynx
Phase of Trial: Phase II
Latest Information Update: 02 Dec 2019
Price : $35 *
At a glance
- Drugs Mosedipimod (Primary) ; Cisplatin
- Indications Stomatitis
- Focus Adverse reactions
- Sponsors Enzychem Lifesciences Corporation
- 17 Jul 2019 Planned number of patients changed from 84 to 104.
- 17 Jul 2019 Planned End Date changed from 20 Jun 2019 to 20 Jun 2020.
- 17 Jul 2019 Planned primary completion date changed from 20 Jun 2019 to 20 Jun 2020.